Moderna Inc.’s stock MRNA rose 3% Wednesday, after the company said it has made regulatory submissions in Europe, Switzerland and Australia for its mRNA-1345 vaccine which targets RSV-associated lower respiratory tract disease and acute respiratory disease in adults aged 60 years or older. The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency, Swissmedic in Switzerland, and the Therapeutic Goods Administration in Australia.
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency, Swissmedic in Switzerland, and the Therapeutic Goods Administration in Australia. The company has also initiated the rolling submission process for a Biologics License Application to the U.S. Food and Drug Administration for the licensure of the mRNA-based RSV vaccine.